[go: up one dir, main page]

MX2015013117A - Composiciones mejoradas para tratar distrofia muscular. - Google Patents

Composiciones mejoradas para tratar distrofia muscular.

Info

Publication number
MX2015013117A
MX2015013117A MX2015013117A MX2015013117A MX2015013117A MX 2015013117 A MX2015013117 A MX 2015013117A MX 2015013117 A MX2015013117 A MX 2015013117A MX 2015013117 A MX2015013117 A MX 2015013117A MX 2015013117 A MX2015013117 A MX 2015013117A
Authority
MX
Mexico
Prior art keywords
improved compositions
treat muscular
muscular distrophy
distrophy
compositions
Prior art date
Application number
MX2015013117A
Other languages
English (en)
Other versions
MX373959B (es
Inventor
Edward M Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2015013117A publication Critical patent/MX2015013117A/es
Publication of MX373959B publication Critical patent/MX373959B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones y métodos mejorados para tratar distrofia muscular, administrando moléculas antisentido capaces de unirse a un sitio objetivo seleccionado en el gen de la distrofina humana para inducir el salto del exones.
MX2015013117A 2013-03-15 2014-03-14 Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd). MX373959B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793463P 2013-03-15 2013-03-15
PCT/US2014/029610 WO2014144978A2 (en) 2013-03-15 2014-03-14 Improved compositions for treating muscular dystrophy

Publications (2)

Publication Number Publication Date
MX2015013117A true MX2015013117A (es) 2016-07-14
MX373959B MX373959B (es) 2020-07-13

Family

ID=50678303

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013117A MX373959B (es) 2013-03-15 2014-03-14 Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
MX2020004986A MX2020004986A (es) 2013-03-15 2015-09-15 Composiciones mejoradas para tratar distrofia muscular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004986A MX2020004986A (es) 2013-03-15 2015-09-15 Composiciones mejoradas para tratar distrofia muscular.

Country Status (14)

Country Link
US (8) US20140329762A1 (es)
EP (2) EP2968991A2 (es)
JP (2) JP2016516066A (es)
KR (2) KR20150133768A (es)
CN (2) CN113633787A (es)
AU (3) AU2014233456B2 (es)
BR (1) BR112015022998A2 (es)
CA (1) CA2906812A1 (es)
EA (1) EA201591792A1 (es)
HK (1) HK1220154A1 (es)
IL (3) IL241558B (es)
MX (2) MX373959B (es)
NZ (2) NZ631289A (es)
WO (1) WO2014144978A2 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1766010T1 (sl) 2004-06-28 2011-06-30 Univ Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
CA3066050A1 (en) 2008-10-24 2010-04-29 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
MX366485B (es) 2013-03-14 2019-07-10 Sarepta Therapeutics Inc Composiciones para el salto de exón para tratamiento de distrofia muscular.
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
AU2016264471B2 (en) 2015-05-19 2022-01-27 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6384845B2 (ja) 2015-09-15 2018-09-05 日本新薬株式会社 アンチセンス核酸
EP3653216A1 (en) * 2015-09-30 2020-05-20 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
KR20180056766A (ko) 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 뉴클레오티드 조성물 및 이의 방법
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EA201891317A3 (ru) * 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
EA201891419A1 (ru) * 2015-12-15 2019-01-31 Сарепта Терапьютикс, Инк. Пептид-олигонуклеотидные конъюгаты
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
BR112018074299A2 (pt) * 2016-05-24 2019-03-12 Sarepta Therapeutics, Inc. composições farmacêuticas compreendendo eteplirsen
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
SG10202101836TA (en) 2016-05-24 2021-03-30 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
PT3464306T (pt) 2016-05-24 2024-05-17 Sarepta Therapeutics Inc Processos para preparar oligómeros morfolino de fosforodiamidato
HRP20241428T1 (hr) 2016-05-24 2025-01-03 Sarepta Therapeutics, Inc. Postupci za pripremu oligomera
EP3478697A1 (en) * 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
CN106581043A (zh) * 2016-10-24 2017-04-26 佳木斯大学 一种适用于杜氏肌营养不良症的药物制剂及其制备方法
EP3545090A1 (en) * 2016-11-28 2019-10-02 The Board of Regents of The University of Texas System Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
DK3554552T3 (da) * 2016-12-19 2022-10-24 Sarepta Therapeutics Inc Exon-skipping-oligomerkonjugater mod muskeldystrofi
PL3554554T3 (pl) 2016-12-19 2022-12-19 Sarepta Therapeutics, Inc. Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
LT3554553T (lt) * 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
SG10202107429WA (en) * 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
EP4403171A3 (en) 2017-06-19 2024-09-11 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same
BR112020001059A2 (pt) 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
KR20200046069A (ko) * 2017-08-31 2020-05-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근디스트로피를 치료하는 방법
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
AU2018335880B2 (en) * 2017-09-22 2025-04-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US20200248178A1 (en) * 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
EP3720448A4 (en) 2017-12-06 2021-11-03 Avidity Biosciences, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
CN111836893A (zh) * 2018-01-31 2020-10-27 德克萨斯大学系统董事会 用于校正人心肌细胞中肌养蛋白突变的组合物和方法
MA52148A (fr) 2018-03-16 2021-01-20 Sarepta Therapeutics Inc Peptides chimères pour administration d'antisens
JP2021521794A (ja) * 2018-04-26 2021-08-30 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
US10765760B2 (en) * 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) * 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP2021526796A (ja) * 2018-06-13 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
BR112020026542A2 (pt) 2018-06-26 2021-04-06 Nippon Shinyaku Co., Ltd. Composição que compreende oligonucleotídeo antissenso e uso da mesma para tratamento de distrofia muscular de duchenne
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2022514954A (ja) 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
CN113518825A (zh) 2018-12-23 2021-10-19 美国杰特贝林生物制品有限公司 Wiskott-aldrich综合征的造血干细胞基因疗法
WO2020157760A1 (en) 2019-01-31 2020-08-06 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
MX2021011498A (es) * 2019-03-28 2022-01-04 Sarepta Therapeutics Inc Metodos para tratar la distrofia muscular con casimersin.
US20220193246A1 (en) * 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP3987029A1 (en) * 2019-06-19 2022-04-27 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EP4007633A4 (en) * 2019-08-02 2024-05-08 Research Institute at Nationwide Children's Hospital EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENOA-ASSOCIATED VIRUS FOR THE TREATMENT OF DYSTROPHIN-BASED MYOPATHIES
EP4051791A4 (en) * 2019-10-30 2023-12-06 Takeda Pharmaceutical Company Limited METHOD FOR DETECTING OLIGONUCLEOTIDES
MY209476A (en) * 2019-12-26 2025-07-11 Nippon Shinyaku Co Ltd Antisense nucleic acid that induces skipping of exon 50
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
US20230256047A1 (en) * 2020-06-17 2023-08-17 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
WO2021263070A1 (en) 2020-06-26 2021-12-30 Csl Behring Llc Donor t-cells with kill switch
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) * 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
IL311507A (en) * 2021-09-16 2024-05-01 Dyne Therapeutics Inc Dosing of muscle targeting complexes for the treatment of dystrophinopathy
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023127918A1 (ja) 2021-12-27 2023-07-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
US20250170259A1 (en) 2022-03-03 2025-05-29 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN119013401A (zh) * 2022-03-17 2024-11-22 萨勒普塔医疗公司 二氨基磷酸酯吗啉代寡聚物缀合物
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
CN115820642B (zh) * 2022-11-11 2023-10-10 昆明理工大学 一种用于治疗杜氏肌营养不良症的CRISPR-Cas9系统

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
DE3687030T2 (de) 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
ES2153379T3 (es) 1992-03-31 2001-03-01 Abbott Lab Procedimiento de reaccion de ligasa en cadena multiplex.
US5869252A (en) 1992-03-31 1999-02-09 Abbott Laboratories Method of multiplex ligase chain reaction
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
DK0698092T3 (da) 1993-05-11 2007-11-26 Univ North Carolina Antisenseoligonukleotider, der bekæmper uregelmæssig splejsning,og fremgangsmåder til anvendelse deraf
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9510718D0 (en) 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
AU2585197A (en) 1996-03-20 1997-10-10 Regents Of The University Of California, The Antisense approach to gene inhibition
US6153436A (en) 1997-01-10 2000-11-28 The Board Of Trustees Of The University Of Arkansas Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US20030114401A1 (en) 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of Ship-1 expression
GB9819999D0 (en) 1998-09-14 1998-11-04 Univ London Treatment of cancer
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
CA2350531A1 (en) 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
KR20010102992A (ko) 1999-01-29 2001-11-17 추후보정 표적 ｒｎａ를 검출하는 비-침입적 방법
US20020049173A1 (en) 1999-03-26 2002-04-25 Bennett C. Frank Alteration of cellular behavior by antisense modulation of mRNA processing
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
AU768904B2 (en) 1999-06-21 2004-01-08 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of medical disorders
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
WO2001047496A1 (en) 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
KR20020079768A (ko) 2000-01-04 2002-10-19 에이브이아이 바이오파마 인코포레이티드 안티센스 항박테리아 세포분열 조성물 및 방법
WO2001072765A1 (en) 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
WO2001083695A2 (en) 2000-04-28 2001-11-08 Xiao Xiao Dna sequences encoding dystrophin minigenes and methods of use thereof
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2002018656A2 (en) 2000-08-30 2002-03-07 Avi Biopharma, Inc. Method for analysis of oligonucleotide analogs
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
EP1319014A1 (en) 2000-09-20 2003-06-18 Isis Pharmaceuticals, Inc. Antisense modulation of flip-c expression
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US6689615B1 (en) 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
JP3781687B2 (ja) 2001-02-23 2006-05-31 松下電器産業株式会社 遺伝子診断装置及び遺伝子診断方法
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250289B2 (en) 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
US7314750B2 (en) 2002-11-20 2008-01-01 Affymetrix, Inc. Addressable oligonucleotide array of the rat genome
CA2507125C (en) 2002-11-25 2014-04-22 Masafumi Matsuo Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ES2500921T3 (es) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células
JP5110877B2 (ja) * 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
ATE387217T1 (de) 2003-07-11 2008-03-15 Lbr Medbiotech B V Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen
CN1829794B (zh) 2003-08-05 2011-06-08 Avi生物制药公司 寡核苷酸类似物和用于治疗黄病毒感染的方法
US20050048495A1 (en) 2003-08-29 2005-03-03 Baker Brenda F. Isoform-specific targeting of splice variants
CA2538729A1 (en) 2003-09-12 2005-03-31 Avi Biopharma, Inc. Compound and method for treating androgen-independent prostate cancer
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
SI1766010T1 (sl) 2004-06-28 2011-06-30 Univ Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
NO20051491L (no) 2005-03-21 2006-09-22 Norsk Hydro As Fremgangsmate og anordning ved en gravitasjonsseparator.
CA2605512A1 (en) 2005-04-22 2006-10-26 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US8524676B2 (en) 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP2535413A3 (en) 2005-11-10 2016-04-13 Roche Innovation Center Copenhagen A/S Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease
US20090011004A1 (en) 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
GB0602767D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
EP2735568B8 (en) 2006-05-10 2017-09-27 Sarepta Therapeutics, Inc. Oligonucleotide analogs having cationic intersubunit linkages
US20070265215A1 (en) 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20090099066A1 (en) 2007-06-29 2009-04-16 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
PL2203173T3 (pl) 2007-10-26 2016-06-30 Academisch Ziekenhuis Leiden Środki i sposoby przeciwdziałania zaburzeniom mięśni
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009101399A1 (en) 2008-02-12 2009-08-20 Isis Innovation Limited Treatment of muscular dystrophy using peptide nucleic acid ( pna)
DK2108366T3 (da) * 2008-04-09 2012-01-30 Santhera Pharmaceuticals Ch Idebenon til behandling af respiratorisk sygdom ved muskeldystrofi
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CA3066050A1 (en) 2008-10-24 2010-04-29 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
CA2741629C (en) 2008-10-27 2022-07-05 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
EP2435583B1 (en) 2009-05-25 2014-07-09 Università degli Studi di Roma "La Sapienza" miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
EP2258863A1 (en) 2009-05-25 2010-12-08 Universita'Degli Studi di Roma "La Sapienza" miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
ITTO20090487A1 (it) 2009-06-26 2010-12-27 Univ Ferrara Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20120172415A1 (en) 2009-08-31 2012-07-05 Thomas Voit Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
IT1397011B1 (it) 2009-10-14 2012-12-20 Univ Ferrara Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
TWI495473B (zh) 2009-11-13 2015-08-11 Sarepta Therapeutics Inc 反義抗病毒化合物及治療流感病毒感染的方法
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
TWI620756B (zh) 2010-05-28 2018-04-11 薩羅塔治療公司 具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
CN106994124A (zh) 2010-06-28 2017-08-01 萩原正敏 遗传性疾病的预防/改善剂
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
KR101764462B1 (ko) 2010-09-30 2017-08-02 니뽄 신야쿠 가부시키가이샤 모르폴리노 핵산 유도체
MX2013009191A (es) 2011-02-08 2013-11-04 Charlotte Mecklenburg Hospital Oligonucleotidos antisentido.
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR102229650B1 (ko) 2011-05-05 2021-03-19 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
WO2013033407A2 (en) 2011-08-30 2013-03-07 The Regents Of The University Of California Identification of small molecules that enhance therapeutic exon skipping
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
ES2736007T3 (es) * 2011-09-05 2019-12-23 Mitsubishi Tanabe Pharma Corp Agente medicinal para el tratamiento de la esclerosis lateral amiotrófica o la prevención de la progresión de una fase de la esclerosis lateral amiotrófica
PL2581448T3 (pl) 2011-10-13 2015-08-31 Association Inst De Myologie Tricyklo-tiofosforanowy DNA
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
ES2706198T3 (es) 2012-03-20 2019-03-27 Sarepta Therapeutics Inc Conjugados de ácido borónico de análogos de oligonucleótidos
CA2877644A1 (en) 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
KR20200143739A (ko) 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
EP3495485A3 (en) 2013-03-14 2019-08-21 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
MX366485B (es) 2013-03-14 2019-07-10 Sarepta Therapeutics Inc Composiciones para el salto de exón para tratamiento de distrofia muscular.
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
JP6461917B2 (ja) 2013-04-20 2019-01-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル エクソン２標的Ｕ７ｓｎＲＮＡポリヌクレオチド構築物の組換えアデノ随伴ウイルスによる送達
ES2987399T3 (es) * 2013-06-05 2024-11-14 Univ Duke Edición génica guiada por ARN y regulación génica
EP3653216A1 (en) 2015-09-30 2020-05-20 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド

Also Published As

Publication number Publication date
AU2020260492A1 (en) 2020-11-26
IL278912A (en) 2021-01-31
BR112015022998A2 (pt) 2017-11-14
EP3662912A1 (en) 2020-06-10
EA201591792A1 (ru) 2016-02-29
NZ631289A (en) 2017-08-25
US10337003B2 (en) 2019-07-02
KR20150133768A (ko) 2015-11-30
CN113633787A (zh) 2021-11-12
IL269845A (en) 2019-11-28
IL241558B (en) 2019-10-31
US20140329762A1 (en) 2014-11-06
US20140315862A1 (en) 2014-10-23
HK1220154A1 (zh) 2017-04-28
US20220403385A1 (en) 2022-12-22
MX2020004986A (es) 2020-08-24
US20190359982A1 (en) 2019-11-28
MX373959B (es) 2020-07-13
CA2906812A1 (en) 2014-09-18
US20180105811A1 (en) 2018-04-19
AU2014233456B2 (en) 2019-02-21
EP2968991A2 (en) 2016-01-20
AU2019203505A1 (en) 2019-06-06
WO2014144978A8 (en) 2014-12-24
US10364431B2 (en) 2019-07-30
US20220033820A1 (en) 2022-02-03
NZ732507A (en) 2018-08-31
CN105307723A (zh) 2016-02-03
US20170283799A1 (en) 2017-10-05
WO2014144978A3 (en) 2014-11-06
AU2014233456A1 (en) 2015-10-08
EP3662912B1 (en) 2025-12-03
KR20200139271A (ko) 2020-12-11
WO2014144978A2 (en) 2014-09-18
US20200040337A1 (en) 2020-02-06
JP2019108349A (ja) 2019-07-04
US9506058B2 (en) 2016-11-29
JP2016516066A (ja) 2016-06-02

Similar Documents

Publication Publication Date Title
MX2015013117A (es) Composiciones mejoradas para tratar distrofia muscular.
MX2015012148A (es) Composiciones para el salto de exón para tratamiento de distrofia muscular.
CY1121876T1 (el) Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας
EA201591178A1 (ru) Улучшенные композиции для пропускания экзона для лечения мышечной дистрофии
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη
PH12017500923A1 (en) New dosage and use of a a2a antagonist
BR112013028891A2 (pt) molécula para tratar um distúrbio inflamatório

Legal Events

Date Code Title Description
FG Grant or registration